Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

ABSTRACT:

Background & aims

Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child-Pugh class B (CP-B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP-B.

Methods

This retrospective study included 796 patients who received Atez/Bev between October 2020 and July 2024 from 10 institutions in Japan. The median observation period was 14.6 months. The liver function was assessed using the CP classification and modified ALBI (mALBI) grade. The progression-free survival (PFS), overall survival (OS) and median survival time (MST) were evaluated.

Results

Patients with CP-B had significantly shorter PFS and O

SUBMITTER: Sasaki R 

PROVIDER: S-EPMC12661480 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature